Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry


ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Research Article

Active Surveillance for Low-risk Prostate Cancer: Are All Criteria Similar?

Author(s): Sebastiano Cimino, Salvatore Privitera, Vincenzo Favilla, Francesco Cantiello, Stefano Manno, Antonio Cicione, Rocco Damiano, Giorgio Ivan Russo* and Giuseppe Morgia

Volume 18 , Issue 7 , 2018

Page: [958 - 963] Pages: 6

DOI: 10.2174/1871520618666180425121617

Price: $65


Background: Active Surveillance (AS) is a therapeutic strategy for early-stage Prostate Cancer (PCa) conceived to balance early detection of aggressive disease and overtreatment of indolent tumor. Several active surveillance protocols have been published over the years, however the risk of misclassification still exist. In this review, we revised the current criteria of AS and evaluated the characteristics of potential risk factors of misclassification or deferred treatment.

Methods: We did a systematic search of the MEDLINE database, from 1993 to May 2015, according to Preferred Reporting Items for Systematic Reviews and Meta-analysis statement guidelines and limited to the English language. The search terms used included “prostate cancer” and “active surveillance” and “criteria. We have excluded from the study reviews and editorial comments as well as multiple papers from the same data sets.

Results: Although the follow-up of reported studies was a quite short compared to the duration of the disease, the data are sufficient to conclude that active surveillance should be offered to men with low-risk disease and to men with intermediate risk and poor life expectancy. The present challenge, in fact, is to differentiate the clinically silent disease from the unfavorable course by identifying the right timing for any deferred treatment. This is made particularly difficult by the absence of randomized controlled trials directly comparing different AS monitoring methods.

Conclusion: As summarized in this review, it is still difficult to select patients eligible for active surveillance and differentiate them from those that should move to active treatment. From the data, currently available in the literature, however, it is possible to recommend active surveillance to men with low-risk disease and to men with intermediate-risk disease but with short life expectancy.

Keywords: Prostate cancer, active surveillance, review, misclassification, low-risk, deferred intervention.

Graphical Abstract

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy